FDA clears Aprea Therapeutic’s Investigational New Drug (IND) application (IND 169359) for oral WEE1 Inhibitor, APR-1051
Aprea to initiate the Phase 1 ACESOT-1051 trial. Learn more

Contact Aprea

Learn more about our DDR-targeted therapeutics, clinical trials, and more.

Please fill out and submit our contact form or write to us directly at [email protected]

3805 Old Easton Rd., Doylestown, PA 18902

Contact Us